Dear readers of ADxS.org, please forgive the disruption.

ADxS.org needs about $19740 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 12,000 times a week, but only 140 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$0 of $19740 - as of 2023-01-03
0%
Header Image
Amilsupride for ADHD

Sitemap

Amilsupride for ADHD

Amilsupride is an atypical antipsychotic.
Amilsupride is a dopamine receptor antagonist.1

Low dose (e.g., 100 mg): primarily blockade of presynaptic (transmitter nerve) D2 and D3 reuptake receptors. This leaves more dopamine in the synaptic cleft for uptake at the postsynapse (receiving nerve), which may alleviate ADHD symptoms.
High dose: Blockade of postsynaptic D2/D3 receptors in the limbic system.

Higher doses (400 mg) of amilsupride can significantly improve excessive affinity for drug-associated stimuli (cue reactivity) and inability to tolerate delayed rewards (reward delay aversion). While cue reactivity was improved as well as by a nonspecific opioid receptor antagonist (naltrexone, 50 mg), the improvement in reward delay aversion by amilsupride was significantly better.2

Amilsupride is mainly used in schizophrenia. Schizophrenia is characterized by dopamine deficiency with regard to negative symptoms and by dopamine excess in the relevant brain areas with regard to positive symptoms.
Some of the negative symptoms of schizophrenia can also be found in a similar form in the spectrum of ADHD symptoms.

Amilsupride is not a typical ADHD medication.

Diese Seite wurde am 08.08.2022 zuletzt aktualisiert.